Tradisionele resepte

Griepinspuitings is veilig vir mense met eierallergieë, nuwe verslagvertonings

Griepinspuitings is veilig vir mense met eierallergieë, nuwe verslagvertonings

Eierallergiese pasiënte het immers nie 'n spesiale griepinspuiting nodig nie

istockphoto.com

'N Nuwe studie toon dat die entstof nie gevaarlik is vir mense met allergieë nie.

Mense met eierallergieë het histories weggebly van die griep -entstof. 'N Opgawe wat op 19 Desember gepubliseer is, dui egter aan dat hierdie bekommernisse oor die eier-gebaseerde skoot verniet was. Die griepinspuiting word as veilig geag, selfs vir diegene met eierallergieë.

"Mense met eierallergie van enige erns kan die griep -entstof ontvang sonder spesiale voorsorgmaatreëls," het dr. Matthew Greenhawt, hoofskrywer van die koerant, aan CNN gesê.

Kenners hoop dat hierdie nuwe onthulling meer mense aanmoedig om griep sonder versigtigheid te kry. Geen griep -entstof is ooit 100 persent effektief nie - verlede jaar se entstof was net 42 persent effektief. Maar dit beteken nie dat u nie een moet kry nie. Die griep -entstof is 'n metode van voorkoming wat deur byna elke dokter en gesondheidspesialis aanbeveel word, insluitend dié by die Centers of Disease Control and Prevention. Tog het slegs 46,8 persent van die mense in die Verenigde State 'n inenting gekry vir die griepseisoen van verlede jaar.

Nie so baie mense vermy die skoot slegs as gevolg van 'n eierallergie nie - slegs twee persent van alle kinders ervaar 'n eierallergie, en dit is selde dat hierdie allergieë tot volwassenheid bestaan.

'' N Verlossende eienskap oor eierallergie is dat die meerderheid daarvan op 'n stadium in die kinderjare uitgegroei het, en dat 'n baie klein aantal mense dit tot volwassenheid behou, 'verduidelik Greenhawt.

Nou is daar nog 'n verskoning om hierdie seisoen u griepinspuiting te vermy - dit is tyd om joune te gaan haal. Voordat u gaan, moet u hierdie 15 dinge opdoen wat u moet weet voordat u ingeënt word.


Inentrasale griep-entstof lyk veilig vir eierallergiese kinders

Kinders met eierallergie kan veilig intranasale dosisse van 'n lewende verswakte griep -entstof (LAIV) ontvang wat met eierproteïen gemaak word, sê ondersoekers uit die Verenigde Koninkryk en Australië.

In 'n fase 4-proefneming het agt van 282 kinders met eierallergie wat een of twee dosisse van die entstof ontvang het, ligte, selfbeperkende simptome gehad wat moontlik aan 'n allergiese reaksie te wyte was, en 26 het binne 72 uur na toediening simptome in die laer lugweë gehad. Nie een van die kinders benodig mediese ingryping vir die reaksies nie, behalwe roetine -behandeling. College London, en die afdeling Immunisasie, Hepatitis en Bloedveiligheid, Openbare Gesondheid Engeland, Londen, Verenigde Koninkryk en die Afdeling Pediatrie en Kindergesondheid, Universiteit van Sydney, Australië en kollegas.

"Hierdie data het 'n veiligheidsprofiel getoon in terme van sistemiese allergiese reaksies op LAIV (verskaf tydens die griepseisoen 2013-2014) by kinders met eierallergie, insluitend dié met 'n vorige anafilakse geskiedenis, soortgelyk aan dié wat voorheen gerapporteer is vir kinders sonder eierallergie. Boonop blyk dit dat die entstof goed verdra word by kinders met asma of herhalende asemhaling, "skryf hulle in 'n artikel wat op 12 Februarie aanlyn in die Journal of Allergy and Clinical Immunology.

Beide geïnaktiveerde en lewendige verswakte vorme van griep -entstof word in henne -eiers gekweek en bevat eierproteïene wat 'n allergiese of anafilaktiese reaksie by kinders met eierallergie kan veroorsaak.

Volgens die advieskomitee oor immuniseringspraktyke van die Centers for Disease Control and Prevention, moet LAIV nie aan persone met eierallergie gegee word nie. In die aanbevelings van die komitee vir die griepseisoen 2014 tot 2015 word daarop gewys dat "persone met 'n geskiedenis van eierallergie wat slegs korwe gehad het nadat hulle aan eier blootgestel is, griep -entstof moet ontvang. Omdat daar relatief min data beskikbaar is vir die gebruik van LAIV in hierdie omgewing, [geïnaktiveer ] of trivalente rekombinante griep -entstof. moet gebruik word. "

In-kantoor administrasie

Dr Turner en kollegas skat dat daar 60 000 kinders in die Verenigde Koninkryk met eierallergie is. Hulle voer aan dat 'n algemene verbod op die gebruik van LAIV in hierdie groep die immuniseringspogings sal belemmer en die koste sal verhoog omdat dit kinders met eierallergie sal benodig om inspuitings van geïnaktiveerde virus te ontvang in 'n kliniese omgewing waar behandeling vir akute allergiese of anafilaktiese reaksies beskikbaar is .

Om te sien of LAIV veilig in 'n breër omgewing toegedien kan word, het hulle 'n studie gedoen met 282 kinders van 2 tot 17 jaar wat gediagnoseer is met 'n immunoglobien E -gemedieerde voedselallergie vir eier. Sensitisering vir eier is bevestig met velprik toetsing.

Altesaam 115 van die kinders (41%) het voorheen anafilakse gehad toe hulle aan eier blootgestel was, en 67% het asma of herhaalde asemhaling gekry, waarvan 51% 'n gewone asma -inhalator of ander vorm van voorkoming gebruik het.

Die kinders het 'n totaal van 433 LAIV-dosisse gekry, sommige kinders het slegs 'n enkele dosis gekry, hoofsaaklik as gevolg van 'n gebrek aan beskikbare inentings.

Daar was 14 newe -effekte by 14 kinders aangemeld binne 2 uur na toediening van entstof. Van hierdie reaksies is agt beskou as 'n moontlike immunoglobien E -gemedieerde reaksie, wat 'n moontlike allergiese reaksietempo van 2,8%tot gevolg het. Die reaksies het ses episodes van rinitis, een geval van gelokaliseerde urtikaria en een geval van ligte ongemak in die spysverteringskanaal ingesluit.

Die oorblywende reaksies, wat alles behalwe een plaasgevind het met die eerste dosis LAIV, het een episode van koors, een ligte ekseemvlam, twee neusobstruksies sonder nasale jeuk of nies, en twee gevalle van verbygaande, nie -gelokaliseerde, nie -spesifieke velsimptome ingesluit. Drie van hierdie kinders het 'n tweede dosis entstof 4 weke later sonder voorval gekry.

Daarbenewens het 26 kinders (9,4%) simptome van die laer lugweë binne 72 uur na toediening van entstof. Uit hierdie groep het 13 asem gekry, soos deur ouers gerapporteer. Nie een van hierdie kinders het meer as roetine mediese ingrype nodig gehad nie, berig die ondersoekers.

'N Spesialis in voedselallergie wat nie by die studie betrokke was nie, het gesê Medscape Mediese Nuus dat die gevolgtrekkings van die studie gesond is.

"Nadat ek na hierdie vraestel gekyk het, voel ek gemaklik om kinders met eierallergie, selfs anafilakse, hierdie intranasale griep -entstof te gee. Die artikel is baie oortuigend en die ontwerp van die studie is baie goed," sê John Leung, besturende direkteur, direkteur van Food Allergy. Sentrum by Tufts Mediese Sentrum en direkteur van die Food Allergy Center in die Floating Hospital for Children, beide in Boston, Massachusetts.

Hy het opgemerk dat die ondersoekers die kinders uitgesluit het wat voorheen meganiese ventilasie nodig gehad het vir 'n anafilaktiese reaksie op eier, ernstige onstabiele asma, of wat voorheen allergiese reaksies op ander komponente van die LAIV as eier gehad het.

Hy het bygevoeg dat praktisyns in die gemeenskap wat kinders met eierallergie behandel en bekommerd is oor moontlike newe-reaksies, die pasiënte kan verwys na 'n voedselallergie-sentrum, waar hulle na 'n entstof toegedien kan word vir 'n uur of langer,

'My ervaring is dat die meeste privaat praktyke nie die mannekrag het om pasiënte 'n uur lank te monitor nie,' het hy gesê.

Die studie is ondersteun deur die UK Department of Health Policy Research Program en deur die plaaslike gesondheidsowerhede. Dr Turner het gerapporteer dat hy navorsingsondersteuning ontvang het van die Britse departement van gesondheid, die UK Medical Research Council en die National Institute for Health Research. Een mede-outeur het ondersteuning ontvang vir die bywoning van wetenskaplike vergaderings van Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals en Thermo Fisher. Die ander skrywers en dr Leung het geen relevante finansiële verhoudings bekend gemaak nie.

Allergie Clin Immunol. Gepubliseer aanlyn 12 Februarie 2015. Volledige teks

Medscape Mediese Nuus © 2015 WebMD, LLC

Stuur kommentaar en nuuswenke aan [email protected]

Noem dit: Intranasale griep -entstof lyk veilig vir eierallergiese kinders - Medscape - 23 Februarie 2015.


Inentrasale griep-entstof lyk veilig vir eierallergiese kinders

Kinders met eierallergie kan veilig intranasale dosisse van 'n lewende verswakte griep -entstof (LAIV) ontvang wat met eierproteïen gemaak word, sê ondersoekers uit die Verenigde Koninkryk en Australië.

In 'n fase 4-studie het agt van 282 kinders met eierallergie wat een of twee dosisse entstof ontvang het, ligte, selfbeperkende simptome gehad wat moontlik aan 'n allergiese reaksie te wyte was, en 26 het binne 72 uur na toediening simptome in die laer lugweë gehad. Nie een van die kinders benodig mediese ingryping vir die reaksies nie, behalwe roetine -behandeling. College London, en die afdeling Immunisasie, Hepatitis en Bloedveiligheid, Openbare Gesondheid Engeland, Londen, Verenigde Koninkryk en die Afdeling Pediatrie en Kindergesondheid, Universiteit van Sydney, Australië en kollegas.

"Hierdie data het 'n veiligheidsprofiel getoon in terme van sistemiese allergiese reaksies op LAIV (verskaf tydens die griepseisoen 2013-2014) by kinders met eierallergie, insluitend dié met 'n vorige anafilakse geskiedenis, soortgelyk aan dié wat voorheen gerapporteer is vir kinders sonder eierallergie. Boonop blyk dit dat die entstof goed verdra word by kinders met asma of herhalende asemhaling, "skryf hulle in 'n artikel wat op 12 Februarie aanlyn in die Journal of Allergy and Clinical Immunology.

Beide geïnaktiveerde en lewendige verswakte vorme van griep -entstof word in henne -eiers gekweek en bevat eierproteïene wat 'n allergiese of anafilaktiese reaksie by kinders met eierallergie kan veroorsaak.

Volgens die advieskomitee oor immuniseringspraktyke van die Centers for Disease Control and Prevention, moet LAIV nie aan persone met eierallergie gegee word nie. In die aanbevelings van die komitee vir die griepseisoen 2014 tot 2015 word opgemerk dat "persone met 'n geskiedenis van eierallergie wat slegs korwe gehad het nadat hulle aan eier blootgestel is, griep -entstof moet ontvang. Omdat daar relatief min data beskikbaar is vir die gebruik van LAIV in hierdie omgewing, [geïnaktiveer ] of trivalente rekombinante griep -entstof. moet gebruik word. "

In-kantoor administrasie

Dr Turner en kollegas skat dat daar 60 000 kinders in die Verenigde Koninkryk met eierallergie is. Hulle voer aan dat 'n algemene verbod op die gebruik van LAIV in hierdie groep die immuniseringspogings sal belemmer en die koste sal verhoog omdat dit kinders met eierallergie sal benodig om inspuitings van geïnaktiveerde virus te ontvang in 'n kliniese omgewing waar behandeling vir akute allergiese of anafilaktiese reaksies beskikbaar is .

Om te sien of LAIV veilig in 'n breër omgewing toegedien kan word, het hulle 'n studie gedoen met 282 kinders van 2 tot 17 jaar wat gediagnoseer is met 'n immunoglobien E -gemedieerde voedselallergie vir eiers. Sensitisering vir eier is bevestig met velprik toetsing.

Altesaam 115 van die kinders (41%) het voorheen anafilakse gehad toe hulle aan eier blootgestel was, en 67% het asma of herhaalde asemhaling gekry, waarvan 51% 'n gewone asma -inhalator of ander vorm van voorkoming gebruik het.

Die kinders het 'n totaal van 433 LAIV-dosisse gekry, sommige kinders het slegs 'n enkele dosis gekry, hoofsaaklik as gevolg van 'n gebrek aan beskikbare in-date-entstof.

Daar was 14 newe -effekte by 14 kinders aangemeld binne 2 uur na toediening van entstof. Van hierdie reaksies is agt beskou as 'n moontlike immunoglobien E -gemedieerde reaksie, wat 'n moontlike allergiese reaksietempo van 2,8%tot gevolg het. Die reaksies het ses episodes van rinitis, een geval van gelokaliseerde urtikaria en een geval van ligte ongemak in die spysverteringskanaal ingesluit.

Die oorblywende reaksies, wat alles behalwe een plaasgevind het met die eerste dosis LAIV, het een episode van koors, een ligte ekseemvlam, twee neusobstruksies sonder neusjeuk of nies, en twee gevalle van verbygaande, nie -gelokaliseerde, nie -spesifieke velsimptome ingesluit. Drie van hierdie kinders het 4 weke later 'n tweede dosis entstof gekry sonder voorval.

Daarbenewens het 26 kinders (9,4%) simptome van die laer lugweë binne 72 uur na toediening van entstof. Uit hierdie groep het 13 asem gehuil, soos deur ouers gerapporteer. Nie een van hierdie kinders het meer as roetine mediese ingrype nodig gehad nie, berig die ondersoekers.

'N Spesialis in voedselallergie wat nie by die studie betrokke was nie, het gesê Medscape Mediese Nuus dat die gevolgtrekkings van die studie gesond is.

"Nadat ek na hierdie vraestel gekyk het, voel ek gemaklik om kinders met eierallergie, selfs anafilakse, hierdie intranasale griep -entstof te gee. Die artikel is baie oortuigend en die ontwerp van die studie is baie goed," sê John Leung, besturende direkteur, direkteur van Food Allergy. Sentrum by Tufts Mediese Sentrum en direkteur van die Food Allergy Center in die Floating Hospital for Children, beide in Boston, Massachusetts.

Hy het opgemerk dat die ondersoekers die kinders uitgesluit het wat voorheen meganiese ventilasie nodig gehad het vir 'n anafilaktiese reaksie op eier, ernstige onstabiele asma, of wat voorheen allergiese reaksies op ander komponente van die LAIV as eier gehad het.

Hy het bygevoeg dat praktisyns in die gemeenskap wat kinders met eierallergie behandel en bekommerd is oor moontlike newe-reaksies, die pasiënte kan verwys na 'n voedselallergie-sentrum, waar hulle 'n uur of langer gemonitor kan word na toediening van die entstof,

'My ervaring is dat die meeste privaat praktyke nie die mannekrag het om pasiënte 'n uur lank te monitor nie,' het hy gesê.

Die studie is ondersteun deur die UK Department of Health Policy Research Program en deur die plaaslike gesondheidsowerhede. Dr Turner het gerapporteer dat hy navorsingsondersteuning ontvang het van die Britse departement van gesondheid, die UK Medical Research Council en die National Institute for Health Research. Een mede-outeur het ondersteuning ontvang vir die bywoning van wetenskaplike vergaderings van Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals en Thermo Fisher. Die ander skrywers en dr Leung het geen relevante finansiële verhoudings bekend gemaak nie.

Allergie Clin Immunol. Gepubliseer aanlyn 12 Februarie 2015. Volledige teks

Medscape Mediese Nuus © 2015 WebMD, LLC

Stuur kommentaar en nuuswenke aan [email protected]

Noem dit: Intranasale griep -entstof lyk veilig vir eierallergiese kinders - Medscape - 23 Februarie 2015.


Inentrasale griep-entstof lyk veilig vir eierallergiese kinders

Kinders met eierallergie kan veilig intranasale dosisse van 'n lewende verswakte griep -entstof (LAIV) ontvang wat met eierproteïen gemaak word, sê ondersoekers uit die Verenigde Koninkryk en Australië.

In 'n fase 4-proefneming het agt van 282 kinders met eierallergie wat een of twee dosisse van die entstof ontvang het, ligte, selfbeperkende simptome gehad wat moontlik aan 'n allergiese reaksie te wyte was, en 26 het binne 72 uur na toediening simptome in die laer lugweë gehad. Nie een van die kinders het mediese ingryping nodig gehad vir die reaksies nie, behalwe roetine -behandeling, meld Paul J. Turner, PhD, van die afdeling vir kindergeneeskunde (allergie en immunologie) en die mediese navorsingsraad en die Astma UK Center in Allergic Mechanisms of Asthma, Imperial College London, en die afdeling Immunisasie, Hepatitis en Bloedveiligheid, Openbare Gesondheid Engeland, Londen, Verenigde Koninkryk en die Afdeling Pediatrie en Kindergesondheid, Universiteit van Sydney, Australië en kollegas.

"Hierdie data het 'n veiligheidsprofiel getoon in terme van sistemiese allergiese reaksies op LAIV (verskaf tydens die griepseisoen 2013-2014) by kinders met eierallergie, insluitend dié met 'n vorige anafilakse geskiedenis, soortgelyk aan dié wat voorheen gerapporteer is vir kinders sonder eierallergie. Boonop blyk dit dat die entstof goed verdra word by kinders met asma of herhalende asemhaling, "skryf hulle in 'n artikel wat op 12 Februarie aanlyn in die Journal of Allergy and Clinical Immunology.

Beide geïnaktiveerde en lewende verswakte vorme van griep -entstof word in henne -eiers gekweek en bevat eierproteïene wat 'n allergiese of anafilaktiese reaksie by kinders met eierallergie kan veroorsaak.

Volgens die advieskomitee oor immuniseringspraktyke van die Centers for Disease Control and Prevention, moet LAIV nie aan persone met eierallergie gegee word nie. In die aanbevelings van die komitee vir die griepseisoen 2014 tot 2015 word opgemerk dat "persone met 'n geskiedenis van eierallergie wat slegs korwe gehad het nadat hulle aan eier blootgestel is, griep -entstof moet ontvang. Omdat daar relatief min data beskikbaar is vir die gebruik van LAIV in hierdie omgewing, [geïnaktiveer ] of trivalente rekombinante griep -entstof. moet gebruik word. "

In-kantoor administrasie

Dr Turner en kollegas skat dat daar 60 000 kinders in die Verenigde Koninkryk met eierallergie is. Hulle voer aan dat 'n algemene verbod op die gebruik van LAIV in hierdie groep die immuniseringspogings sal belemmer en die koste sal verhoog omdat dit kinders met eierallergie sal benodig om inspuitings van geïnaktiveerde virus te ontvang in 'n kliniese omgewing waar behandeling vir akute allergiese of anafilaktiese reaksies beskikbaar is .

Om te sien of LAIV veilig in 'n breër omgewing toegedien kan word, het hulle 'n studie gedoen met 282 kinders van 2 tot 17 jaar wat gediagnoseer is met 'n immunoglobien E -gemedieerde voedselallergie vir eiers. Sensitisering vir eier is bevestig met velprik toetsing.

Altesaam 115 van die kinders (41%) het voorheen anafilakse gehad toe hulle aan eier blootgestel was, en 67% het asma of herhaalde asemhaling gekry, waarvan 51% 'n gewone asma -inhalator of ander vorm van voorkoming gebruik het.

Die kinders het 'n totaal van 433 LAIV-dosisse gekry, sommige kinders het slegs 'n enkele dosis gekry, hoofsaaklik as gevolg van 'n gebrek aan beskikbare in-date-entstof.

Daar was 14 newe -effekte by 14 kinders aangemeld binne 2 uur na toediening van entstof. Van hierdie reaksies is agt beskou as 'n moontlike immunoglobien E -gemedieerde reaksie, wat 'n moontlike allergiese reaksietempo van 2,8%tot gevolg kan hê. Die reaksies het ses episodes van rinitis, een geval van gelokaliseerde urtikaria en een geval van ligte ongemak in die spysverteringskanaal ingesluit.

Die oorblywende reaksies, wat alles behalwe een plaasgevind het met die eerste dosis LAIV, het een episode van koors, een ligte ekseemvlam, twee neusobstruksies sonder nasale jeuk of nies, en twee gevalle van verbygaande, nie -gelokaliseerde, nie -spesifieke velsimptome ingesluit. Drie van hierdie kinders het 4 weke later 'n tweede dosis entstof gekry sonder voorval.

Daarbenewens het 26 kinders (9,4%) simptome van die laer lugweë binne 72 uur na toediening van entstof. Uit hierdie groep het 13 asem gekry, soos deur ouers gerapporteer. Nie een van hierdie kinders het meer as roetine mediese ingrype nodig gehad nie, berig die ondersoekers.

'N Spesialis in voedselallergie wat nie by die studie betrokke was nie, het gesê Medscape Mediese Nuus dat die gevolgtrekkings van die studie gesond is.

"Nadat ek na hierdie vraestel gekyk het, voel ek gemaklik om kinders met eierallergie, selfs anafilakse, hierdie intranasale griep -entstof te gee. Die artikel is baie oortuigend en die ontwerp van die studie is baie goed," sê John Leung, besturende direkteur, direkteur van Food Allergy. Sentrum by Tufts Mediese Sentrum en direkteur van die Food Allergy Center in die Floating Hospital for Children, beide in Boston, Massachusetts.

Hy het opgemerk dat die ondersoekers die kinders uitgesluit het wat voorheen meganiese ventilasie nodig gehad het vir 'n anafilaktiese reaksie op eier, ernstige onstabiele asma, of wat voorheen allergiese reaksies op ander komponente van die LAIV as eier gehad het.

Hy het bygevoeg dat praktisyns in die gemeenskap wat kinders met eierallergie behandel en bekommerd is oor moontlike newe-reaksies, die pasiënte kan verwys na 'n voedselallergie-sentrum, waar hulle 'n uur of langer gemonitor kan word na toediening van die entstof,

'My ervaring is dat die meeste privaat praktyke nie die mannekrag het om pasiënte 'n uur lank te monitor nie,' het hy gesê.

Die studie is ondersteun deur die UK Department of Health Policy Research Program en deur die plaaslike gesondheidsowerhede. Dr Turner het gerapporteer dat hy navorsingsondersteuning ontvang het van die Britse departement van gesondheid, die UK Medical Research Council en die National Institute for Health Research. Een mede-outeur het ondersteuning ontvang vir die bywoning van wetenskaplike vergaderings van Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals en Thermo Fisher. Die ander skrywers en dr Leung het geen relevante finansiële verhoudings bekend gemaak nie.

Allergie Clin Immunol. Gepubliseer aanlyn 12 Februarie 2015. Volledige teks

Medscape Mediese Nuus © 2015 WebMD, LLC

Stuur kommentaar en nuuswenke aan [email protected]

Noem dit: Intranasale griep -entstof lyk veilig vir eierallergiese kinders - Medscape - 23 Februarie 2015.


Inentrasale griep-entstof lyk veilig vir eierallergiese kinders

Kinders met eierallergie kan veilig intranasale dosisse van 'n lewende verswakte griep -entstof (LAIV) ontvang wat met eierproteïen gemaak word, sê ondersoekers uit die Verenigde Koninkryk en Australië.

In 'n fase 4-proefneming het agt van 282 kinders met eierallergie wat een of twee dosisse van die entstof ontvang het, ligte, selfbeperkende simptome gehad wat moontlik aan 'n allergiese reaksie te wyte was, en 26 het binne 72 uur na toediening simptome in die laer lugweë gehad. Nie een van die kinders benodig mediese ingryping vir die reaksies nie, behalwe roetine -behandeling. College London, en die afdeling Immunisering, Hepatitis en Bloedveiligheid, Openbare Gesondheid Engeland, Londen, Verenigde Koninkryk en die Afdeling Kindergeneeskunde en Kindergesondheid, Universiteit van Sydney, Australië en kollegas.

"Hierdie data het 'n veiligheidsprofiel getoon in terme van sistemiese allergiese reaksies op LAIV (verskaf tydens die griepseisoen 2013-2014) by kinders met eierallergie, insluitend dié met 'n vorige anafilakse geskiedenis, soortgelyk aan dié wat voorheen gerapporteer is vir kinders sonder eierallergie. Boonop blyk dit dat die entstof goed verdra word by kinders met asma of herhalende asemhaling, "skryf hulle in 'n artikel wat op 12 Februarie aanlyn in die Journal of Allergy and Clinical Immunology.

Beide geïnaktiveerde en lewendige verswakte vorme van griep -entstof word in henne -eiers gekweek en bevat eierproteïene wat 'n allergiese of anafilaktiese reaksie by kinders met eierallergie kan veroorsaak.

Volgens die advieskomitee oor immuniseringspraktyke van die Centers for Disease Control and Prevention, moet LAIV nie aan persone met eierallergie gegee word nie. In die aanbevelings van die komitee vir die griepseisoen 2014 tot 2015 word daarop gewys dat "persone met 'n geskiedenis van eierallergie wat slegs korwe gehad het nadat hulle aan eier blootgestel is, griep -entstof moet ontvang. Omdat daar relatief min data beskikbaar is vir die gebruik van LAIV in hierdie omgewing, [geïnaktiveer ] of trivalente rekombinante griep -entstof. moet gebruik word. "

In-kantoor administrasie

Dr Turner en kollegas skat dat daar 60 000 kinders in die Verenigde Koninkryk met eierallergie is. Hulle voer aan dat 'n algemene verbod op die gebruik van LAIV in hierdie groep die immuniseringspogings sal belemmer en die koste sal verhoog omdat dit kinders met eierallergie sal benodig om inspuitings van geïnaktiveerde virus te ontvang in 'n kliniese omgewing waar behandeling vir akute allergiese of anafilaktiese reaksies beskikbaar is .

Om te sien of LAIV veilig in 'n breër omgewing toegedien kan word, het hulle 'n studie gedoen met 282 kinders van 2 tot 17 jaar wat gediagnoseer is met 'n immunoglobien E -gemedieerde voedselallergie vir eiers. Sensitisering vir eier is bevestig met velprik toetsing.

Altesaam 115 van die kinders (41%) het voorheen anafilakse gehad toe hulle aan eier blootgestel was, en 67% het asma of herhaalde asemhaling gekry, waarvan 51% 'n gewone asma -inhalator of ander vorm van voorkoming gebruik het.

Die kinders het 'n totaal van 433 LAIV-dosisse gekry, sommige kinders het slegs 'n enkele dosis gekry, hoofsaaklik as gevolg van 'n gebrek aan beskikbare in-date-entstof.

Daar was 14 newe -effekte by 14 kinders aangemeld binne 2 uur na toediening van entstof. Van hierdie reaksies is agt beskou as 'n moontlike immunoglobien E -gemedieerde reaksie, wat 'n moontlike allergiese reaksietempo van 2,8%tot gevolg kan hê. Die reaksies het ses episodes van rinitis, een geval van gelokaliseerde urtikaria en een geval van ligte ongemak in die spysverteringskanaal ingesluit.

Die oorblywende reaksies, wat alles behalwe een plaasgevind het met die eerste dosis LAIV, het een episode van koors, een ligte ekseemvlam, twee neusobstruksies sonder nasale jeuk of nies, en twee gevalle van verbygaande, nie -gelokaliseerde, nie -spesifieke velsimptome ingesluit. Drie van hierdie kinders het 'n tweede dosis entstof 4 weke later sonder voorval gekry.

Daarbenewens het 26 kinders (9,4%) simptome van die laer lugweë binne 72 uur na toediening van entstof. Uit hierdie groep het 13 asem gehuil, soos deur ouers gerapporteer. Nie een van hierdie kinders het meer as roetine mediese ingrype nodig gehad nie, berig die ondersoekers.

'N Spesialis in voedselallergie wat nie by die studie betrokke was nie, het gesê Medscape Mediese Nuus dat die gevolgtrekkings van die studie gesond is.

"Nadat ek na hierdie vraestel gekyk het, voel ek gemaklik om kinders met eierallergie, selfs anafilakse, hierdie intranasale griep -entstof te gee. Die artikel is baie oortuigend en die ontwerp van die studie is baie goed," sê John Leung, besturende direkteur, direkteur van Food Allergy. Sentrum by Tufts Mediese Sentrum en direkteur van die Food Allergy Center in die Floating Hospital for Children, beide in Boston, Massachusetts.

Hy het opgemerk dat die ondersoekers die kinders uitgesluit het wat voorheen meganiese ventilasie nodig gehad het vir 'n anafilaktiese reaksie op eier, ernstige onstabiele asma, of wat voorheen allergiese reaksies op ander komponente van die LAIV as eier gehad het.

Hy het bygevoeg dat praktisyns in die gemeenskap wat kinders met eierallergie behandel en bekommerd is oor moontlike newe-reaksies, die pasiënte kan verwys na 'n voedselallergie-sentrum, waar hulle na 'n entstof toegedien kan word vir 'n uur of langer,

'My ervaring is dat die meeste privaat praktyke nie die mannekrag het om pasiënte 'n uur lank te monitor nie,' het hy gesê.

Die studie is ondersteun deur die UK Department of Health Policy Research Program en deur die plaaslike gesondheidsowerhede. Dr Turner het gerapporteer dat hy navorsingsondersteuning ontvang het van die Britse departement van gesondheid, die UK Medical Research Council en die National Institute for Health Research. Een mede-outeur het ondersteuning ontvang vir die bywoning van wetenskaplike vergaderings van Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals en Thermo Fisher. Die ander skrywers en dr Leung het geen relevante finansiële verhoudings bekend gemaak nie.

Allergie Clin Immunol. Gepubliseer aanlyn 12 Februarie 2015. Volledige teks

Medscape Mediese Nuus © 2015 WebMD, LLC

Stuur kommentaar en nuuswenke aan [email protected]

Noem dit: Intranasale griep -entstof lyk veilig vir eierallergiese kinders - Medscape - 23 Februarie 2015.


Inentrasale griep-entstof lyk veilig vir eierallergiese kinders

Kinders met eierallergie kan veilig intranasale dosisse van 'n lewende verswakte griep -entstof (LAIV) ontvang wat met eierproteïen gemaak word, sê ondersoekers uit die Verenigde Koninkryk en Australië.

In 'n fase 4-studie het agt van 282 kinders met eierallergie wat een of twee dosisse entstof ontvang het, ligte, selfbeperkende simptome gehad wat moontlik aan 'n allergiese reaksie te wyte was, en 26 het binne 72 uur na toediening simptome in die laer lugweë gehad. Nie een van die kinders benodig mediese ingryping vir die reaksies nie, behalwe roetine -behandeling. College London, en die afdeling Immunisering, Hepatitis en Bloedveiligheid, Openbare Gesondheid Engeland, Londen, Verenigde Koninkryk en die Afdeling Kindergeneeskunde en Kindergesondheid, Universiteit van Sydney, Australië en kollegas.

"Hierdie data het 'n veiligheidsprofiel getoon in terme van sistemiese allergiese reaksies op LAIV (verskaf tydens die griepseisoen 2013-2014) by kinders met eierallergie, insluitend dié met 'n vorige anafilakse geskiedenis, soortgelyk aan dié wat voorheen gerapporteer is vir kinders sonder eierallergie. Boonop blyk dit dat die entstof goed verdra word by kinders met asma of herhalende asemhaling, "skryf hulle in 'n artikel wat op 12 Februarie aanlyn in die Journal of Allergy and Clinical Immunology.

Beide geïnaktiveerde en lewendige verswakte vorme van griep -entstof word in henne -eiers gekweek en bevat eierproteïene wat 'n allergiese of anafilaktiese reaksie by kinders met eierallergie kan veroorsaak.

Volgens die advieskomitee oor immuniseringspraktyke van die Centers for Disease Control and Prevention, moet LAIV nie aan persone met eierallergie gegee word nie. In die aanbevelings van die komitee vir die griepseisoen 2014 tot 2015 word daarop gewys dat "persone met 'n geskiedenis van eierallergie wat slegs korwe gehad het nadat hulle aan eier blootgestel is, griep -entstof moet ontvang. Omdat daar relatief min data beskikbaar is vir die gebruik van LAIV in hierdie omgewing, [geïnaktiveer ] of trivalente rekombinante griep -entstof. moet gebruik word. "

In-kantoor administrasie

Dr Turner en kollegas skat dat daar 60 000 kinders in die Verenigde Koninkryk met eierallergie is. Hulle voer aan dat 'n algemene verbod op die gebruik van LAIV in hierdie groep die immuniseringspogings sal belemmer en die koste sal verhoog omdat dit kinders met eierallergie sal benodig om inspuitings van geïnaktiveerde virus te ontvang in 'n kliniese omgewing waar behandeling vir akute allergiese of anafilaktiese reaksies beskikbaar is .

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids

Children with egg allergy can safely receive intranasal doses of a live attenuated influenza vaccine (LAIV) made with egg protein, say investigators from the United Kingdom and Australia.

In a phase 4 trial, eight of 282 children with egg allergy who received one or two doses of the vaccine had mild, self-limiting symptoms possibly attributable to an allergic reaction, and 26 had lower respiratory tract symptoms within 72 hours of administration. None of the children required medical intervention for the reactions other than routine treatment, however, report Paul J. Turner, PhD, from the Section of Paediatrics (Allergy & Immunology) and Medical Research Council & Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, and the Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom and the Division of Paediatrics and Child Health, University of Sydney, Australia, and colleagues.

"[T]hese data have demonstrated a safety profile in terms of systemic allergic reactions to LAIV (supplied during the 2013-2014 influenza season) in children with egg allergy, including those with a prior history of anaphylaxis, similar to that previously reported for children without egg allergy. Furthermore, the vaccine appears to be well tolerated in children with a diagnosis of asthma or recurrent wheeze," they write in an article published online February 12 in the Journal of Allergy and Clinical Immunology.

Both inactivated and live attenuated forms of influenza vaccine are cultured in hens' eggs and contain egg proteins that have the potential to spark an allergic or anaphylactic reaction in children with egg allergy.

According to the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, LAIV should not be given to persons with egg allergy. The committee's recommendations for the 2014 to 2015 influenza season note that "persons with a history of egg allergy who have experienced only hives after exposure to egg should receive influenza vaccine. Because relatively few data are available for use of LAIV in this setting, [inactivated] or trivalent recombinant influenza vaccine. should be used."

In-Office Administration

Dr Turner and colleagues estimate that there are 60,000 children in the United Kingdom with egg allergy. A blanket injunction against the use of LAIV in this group, they argue, would hamper immunization efforts and raise costs because it would require children with egg allergy to receive injections of inactivated virus in a clinical setting where treatment for acute allergic or anaphylactic reactions are available.

To see whether LAIV could be safely administered in a broader setting, they conducted a study with 282 children from the ages of 2 through 17 years who had been diagnosed with an immunoglobin E–mediated food allergy to egg. Sensitization to egg was confirmed with skin-prick testing.

In all, 115 of the children (41%) had previously had anaphylaxis when exposed to egg, and 67% had a diagnosis of asthma or recurrent wheeze, of whom 51% were using a regular asthma inhaler or other form of prevention.

The children received a total of 433 LAIV doses some children received only a single dose, primarily because of a lack of available in-date vaccine.

There were 14 adverse events reported in 14 children within 2 hours of vaccine administration. Of these reactions, eight were considered to be a potential immunoglobin E–mediated response, resulting in a potential allergic response rate of 2.8%. The reactions included six episodes of rhinitis, one case of localized urticaria, and one case of mild gastrointestinal discomfort, The reactions were mild and self-limiting, and all occurred within a half-hour of vaccine administration.

The remaining reactions, all but one of which occurred with the first dose of LAIV, included one episode of fever, one mild eczema flare, two nasal obstructions without nasal itch or sneezing, and two cases of transient, nonlocalized, nonspecific skin symptoms. Three of these children had a second dose of vaccine 4 weeks later without incident.

In addition, 26 children (9.4%) had lower respiratory tract symptoms within 72 hours of vaccine administration. Of this group, 13 had wheeze, as reported by parents. None of these children required more than routine medical interventions, the investigators report.

A food-allergy specialist who was not involved in the study told Medscape Medical News that the study's conclusions are sound.

"After looking at this paper, I feel comfortable giving kids with egg allergy, even anaphylaxis, this intranasal influenza vaccine. The article is very convincing, and the study design is very good," said John Leung, MD, director of the Food Allergy Center at Tufts Medical Center and codirector of the Food Allergy Center at the Floating Hospital for Children, both in Boston, Massachusetts.

He noted that the investigators excluded from their study those children who had previously required mechanical ventilation for an anaphylactic reaction to egg, severe unstable asthma, or who had prior allergic reactions to components of the LAIV other than egg.

He added that community-based practitioners who treat children with egg allergy and are concerned about potential adverse reactions can refer the patients to a food allergy center, where they can be monitored for an hour or more after vaccine administration,

"My experience is that majority of private practices don't have the manpower to monitor patients for an hour," he said.

The study was supported by the UK Department of Health Policy Research Programme and by local health authorities. Dr Turner reported receiving research support from the UK Department of Health, the UK Medical Research Council, and the National Institute for Health Research. One coauthor has received support for attendance at scientific meetings from Allergy Therapeutics, ALK-Abello, MEDA Pharmaceuticals, and Thermo Fisher. The other authors and Dr Leung have disclosed no relevant financial relationships.

Allergy Clin Immunol. Published online February 12, 2015. Full text

Medscape Medical News © 2015 WebMD, LLC

Send comments and news tips to [email protected]

Cite this: Intranasal Flu Vaccine Appears Safe for Egg-Allergic Kids - Medscape - Feb 23, 2015.


Kyk die video: Дубынин В. А. - Физиология иммунитета - Грипп и коронавирус (Desember 2021).